Global Newcastle Disease Vaccine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Newcastle Disease Vaccine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Pharmaceutical
  • Upcoming Report
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Newcastle Disease Vaccine Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Newcastle Disease Vaccine Market size in 2024 - 312.45 and 2032 - 430.58, highlighting the projected market growth. USD 312.45 Million USD 430.58 Million 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 312.45 Million
Diagram Market Size (Forecast Year)
USD 430.58 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Newcastle Disease Vaccine Market Segmentation, By Type of VaccineLive Attenuated VaccinesInactivated Vaccines, Vector-based Vaccines, DNA Vaccines, and Others), Route of Administration (Subcutaneous, Intramuscular, Oral, Intranasal, and Others), Target Species (Chicken, Duck and Goose, and Other Poultry), Formulation (Lyophilized, Liquid, Suspension, and Emulsion), End-User (Commercial Poultry Farms, Backyard Poultry Farmers, Veterinary Clinics, and Research Institutions)– Industry Trends and Forecast to 2032

Newcastle Disease Vaccine Market

Newcastle Disease Vaccine Market Analysis

The Newcastle Disease Vaccine Market has shown significant growth due to the increasing awareness of poultry health and the rising demand for sustainable farming practices. Poultry farming remains a crucial part of global agriculture, with vaccines playing a pivotal role in managing and preventing Newcastle Disease, a highly contagious viral infection that affects birds. The market is driven by the need to protect poultry from the virus, ensuring better yield and productivity in the industry.

The market is primarily driven by the growing demand for poultry products and the continuous expansion of commercial poultry farming worldwide. Innovations in vaccine development, such as improved efficacy, longer-lasting immunity, and more cost-effective solutions, have contributed to the growing adoption of these vaccines. In addition, increased government support for vaccination programs and a shift toward biosecurity measures in poultry farming have spurred market growth.

Moreover, advancements in biotechnology have led to the development of new vaccine types, including recombinant vaccines, which offer enhanced protection and fewer side effects. With a focus on disease prevention and minimizing the impact of Newcastle Disease, the market is expected to see further expansion, attracting more investments in research and development. The market will likely continue to grow as global poultry production expands and the importance of animal health becomes more recognized in the agricultural industry.

Newcastle Disease Vaccine Market Size

The global Newcastle disease vaccine market size was valued at USD 312.45 million in 2024 and is projected to reach USD 430.58 million by 2032, with a CAGR of 4.09% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Newcastle Disease Vaccine Market Trends

“Rising global demand for poultry products”

The Newcastle Disease Vaccine Market is experiencing robust growth driven by key market trends such as the rising global demand for poultry products and an increasing focus on animal health management. Newcastle Disease (ND) remains a significant threat to poultry, making vaccination a vital strategy for safeguarding flock health and minimizing production losses. As poultry farming continues to grow, particularly in emerging markets, the need for effective vaccines has surged.

Innovative vaccine technologies, including recombinant and thermostable vaccines, have significantly improved vaccine efficacy, safety, and user convenience, boosting adoption rates. In addition, growing awareness of biosecurity measures and the emphasis on disease prevention within the poultry industry are further propelling market expansion. Increased support from governments and agricultural organizations for vaccination programs has strengthened efforts to control ND outbreaks. These market dynamics are driving higher demand for Newcastle Disease vaccines, contributing to the sustained growth of the market.

Report Scope and Newcastle Disease Vaccine Market Segmentation

Attributes

Newcastle Disease Vaccine Key Market Insights

Segments Covered

  • By Type of Vaccine: Live Attenuated Vaccines, Inactivated Vaccines, Vector-based Vaccines, DNA Vaccines, and Others),
  • By Route of Administration: Subcutaneous, Intramuscular, Oral, Intranasal, and Others
  • By Target Species: Chicken, Duck, Goose, and Other Poultry
  • By Formulation: Lyophilized, Liquid, Suspension, and Emulsion
  • By End-User: Commercial Poultry Farms, Backyard Poultry Farmers, Veterinary Clinics, and Research Institutions

Countries Covered

U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America

Key Market Players

Bimeda Corporate (Ireland), BIO-MED (India), Boehringer Ingelheim International GmbH (Germany), Biovac (Israel), Cargill, Incorporated (U.S.), Ceva (France), Elanco or its affiliates (U.S.), FATRO S.p.A. (Italy), Harbin Veterinary Research Institute (HVRI) (China), HESTER BIOSCIENCES LIMITED (India), Huvepharma (Bulgaria), Merck & Co., Inc. (U.S.), Phibro Animal Health Corporation (U.S.), SAN Group Biotech Germany GmbH (Germany), TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. (China), VAKSINDO ANIMAL HEALTH PVT. LTD (India), Vaxxinova International BV (The Netherlands), VETVACO NATIONAL VETERINARY JOINT-STOCK COMPANY (Vietnam), Venkys India (India), YEBIO BIOENGINEERING CO., LTD OF QINGDAO (China) and Zoetis Services LLC (U.S.)

Market Opportunities

  • Expansion into Emerging Markets
  • Technological Innovations in Vaccine Delivery

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Newcastle Disease Vaccine Market Definition

The Newcastle Disease Vaccine is a biological product used to prevent Newcastle Disease (ND), a highly contagious viral infection that affects various bird species, particularly poultry. The vaccine works by stimulating the immune system of birds to produce antibodies against the Newcastle Disease virus (NDV), thereby providing immunity and protecting the flock from potential outbreaks. There are different types of vaccines available, including live attenuated vaccines, inactivated vaccines, and recombinant vaccines, each designed to offer effective protection with varying levels of safety, efficacy, and ease of administration. Vaccination is a key component of biosecurity programs in poultry farming, aimed at controlling the spread of the disease and maintaining the health and productivity of poultry flocks.

Newcastle Disease Vaccine Market Dynamics

Drivers

  • Increasing Awareness of Biosecurity and Disease Prevention

The growing awareness of biosecurity and the importance of disease prevention in poultry farming is a key driver of the Newcastle disease vaccine market. As the poultry industry becomes more industrialized and integrated, there is a stronger focus on maintaining healthy flocks to prevent disease outbreaks, which can lead to significant economic losses. Farmers are increasingly adopting comprehensive biosecurity measures, including vaccination, to safeguard their poultry operations. For instance, in countries such as the United States and Brazil, where large-scale commercial poultry farming is common, strict vaccination protocols are implemented to prevent Newcastle Disease and other infectious diseases. This heightened focus on disease prevention, driven by both economic factors and regulatory pressures, has led to a surge in vaccine adoption. As awareness of the risks associated with ND and the effectiveness of vaccines continues to grow, more poultry producers are investing in vaccination programs, further fueling market expansion.

  • Advancements in Vaccine Technology

Advancements in vaccine technology have significantly boosted the Newcastle disease vaccine market. Innovations such as recombinant and thermostable vaccines have improved vaccine effectiveness, ease of use, and storage capabilities, making them more accessible, especially in remote areas with limited refrigeration infrastructure. Recombinant vaccines, for instance, offer better protection and fewer side effects compared to traditional vaccines, while thermostable vaccines are designed to withstand high temperatures, making distribution easier. A notable instance is the thermostable ND vaccine developed by Merck Animal Health, which has improved vaccine accessibility in regions with less reliable cold chains, such as parts of Africa and Southeast Asia. These technological advancements have made vaccination more practical, increasing adoption rates and driving demand for ND vaccines globally. With the poultry sector becoming increasingly dependent on these innovations for disease prevention, the market for Newcastle Disease vaccines is expected to continue growing.

Opportunities

  • Expansion into Emerging Markets

One of the key opportunities for the Newcastle disease vaccine market lies in its expansion into emerging markets, particularly in regions such as Africa, Asia, and Latin America. These areas are experiencing rapid growth in poultry farming, driven by increasing population and rising demand for protein sources such as chicken. However, these regions often lack robust biosecurity measures, making them more susceptible to Newcastle disease outbreaks. This presents a significant opportunity for vaccine manufacturers to expand their presence by providing affordable, effective vaccines tailored to local needs. For instance, in Africa, countries such as Nigeria and Ethiopia have been implementing vaccination programs to control Newcastle disease outbreaks and improve poultry productivity. As these markets continue to grow, the demand for vaccines to prevent Newcastle disease will rise, creating new avenues for market players to introduce cost-effective and easy-to-use vaccine solutions.

  • Technological Innovations in Vaccine Delivery

Technological advancements in vaccine delivery systems represent another major opportunity for the ND vaccine market. New delivery methods, such as oral vaccines or aerosol vaccines, are becoming increasingly popular due to their ease of administration and ability to reach large populations of poultry more efficiently. Oral vaccines, for instance, simplify the vaccination process, reducing labor costs and stress for the animals, which makes them attractive to large-scale poultry producers. Companies such as Zoetis and Merck are investing in research to develop these innovative delivery methods. In addition, the advent of thermostable vaccines has enabled broader distribution, even in regions without reliable cold chain infrastructure. These technological innovations present a significant opportunity to increase vaccine access and adoption, especially in remote areas, thereby expanding the market potential for Newcastle Disease vaccines worldwide.

Restraints/Challenges

  • High Cost of Vaccines

A major restraint in the Newcastle Disease vaccine market is the high cost of vaccines, which can limit accessibility for small-scale poultry farmers, particularly in developing regions. Although vaccines are essential for disease prevention, the financial burden of purchasing vaccines, along with the cost of administration, can be prohibitive for farmers with limited resources. For instance, in countries such as India and Nigeria, where a significant portion of poultry farming is small-scale and economically constrained, the cost of vaccines can deter farmers from adopting regular vaccination practices. This financial challenge is compounded by the fact that some vaccines require multiple doses or special storage conditions, such as refrigeration, adding to the overall cost. As a result, the market faces barriers to widespread vaccine adoption, which can hinder efforts to control Newcastle Disease in these regions.

  • Vaccine Efficacy and Resistance Issues

Another challenge facing the Newcastle Disease vaccine market is concerns over vaccine efficacy and the potential development of resistance. Although vaccines are generally effective in preventing ND, variations in the virus and environmental conditions can sometimes affect the performance of vaccines, leading to inconsistent results. In addition, improper administration or poor storage conditions, common in rural and resource-limited areas, can reduce vaccine effectiveness. For instance, the use of live attenuated vaccines, while effective, can sometimes lead to suboptimal immune responses if not stored or administered correctly. This poses a challenge in maintaining consistent vaccine protection, particularly in regions with limited access to proper healthcare infrastructure. Consequently, maintaining high standards of vaccine administration and ensuring the development of more robust vaccines are ongoing challenges in the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Newcastle Disease Vaccine Market Scope

The market is segmented on the basis of type of vaccine, route of administration, target species, formulation, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type of Vaccine

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Vector-based Vaccines
  • DNA Vaccines
  • Others

Route of Administration

  • Subcutaneous
  • Intramuscular
  • Oral
  • Intranasal
  • Others

Target Species

  • Chicken
  • Duck
  • Goose
  • Other Poultry

Formulation

  • Lyophilized
  • Liquid
  • Suspension
  • Emulsion

End-User

  • Commercial Poultry Farms
  • Backyard Poultry Farmers
  • Veterinary Clinics
  • Research Institutions

Newcastle Disease Vaccine Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type of vaccine, route of administration, target species, formulation, and end-user. as referenced above.

The countries covered in the market report are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

North America is expected to dominate the global Newcastle Disease vaccine market, primarily due to its large-scale poultry production, strict biosecurity regulations, and a strong focus on food safety. The United States, as one of the world’s largest producers and consumers of poultry products, has a significant demand for effective disease prevention measures to ensure the health of its poultry flocks. With consumer awareness around food safety on the rise, maintaining disease-free poultry is crucial to safeguarding product quality and consumer confidence. In addition, the U.S. government plays a key role in supporting vaccination programs through regulations and initiatives aimed at preventing avian diseases. These factors, coupled with advanced agricultural practices and strong veterinary infrastructure, position North America as the dominant player in the Newcastle Disease vaccine market and ensure its continued leadership in the industry.

The Asia-Pacific (APAC) Newcastle Disease vaccine market is expected to grow at the fastest CAGR from 2024 to 2032. This growth is driven by several factors, including the rapid expansion of the poultry industry in countries such as China, India, and Southeast Asia, where the demand for poultry products continues to rise due to population growth and increasing disposable incomes. In these regions, poultry farming is becoming more industrialized, leading to higher adoption of vaccines to ensure the health and productivity of poultry flocks. In addition, the awareness of biosecurity measures and the importance of disease prevention, including vaccination, is growing rapidly among farmers. This, combined with government initiatives to support vaccination programs and improve poultry health, further fuels market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Newcastle Disease Vaccine Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Newcastle Disease Vaccine Market Leaders Operating in the Market Are:

  • Bimeda Corporate (Ireland)
  • BIO-MED (India)
  • Boehringer Ingelheim International GmbH (Germany)
  • Biovac (Israel)
  • Cargill, Incorporated (U.S.)
  • Ceva (France)
  • Elanco or its affiliates (U.S.)
  • FATRO S.p.A. (Italy)
  • Harbin Veterinary Research Institute (HVRI) (China)
  • HESTER BIOSCIENCES LIMITED (India)
  • Huvepharma (Bulgaria)
  • Merck & Co., Inc. (U.S.)
  • Phibro Animal Health Corporation (U.S.)
  • SAN Group Biotech Germany GmbH (Germany)
  • TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. (China)
  • VAKSINDO ANIMAL HEALTH PVT. LTD (India)
  • Vaxxinova International BV (The Netherlands)
  • VETVACO NATIONAL VETERINARY JOINT-STOCK COMPANY (Vietnam)
  • Venkys India (India)
  • YEBIO BIOENGINEERING CO., LTD OF QINGDAO (China)
  • Zoetis Services LLC (U.S.)

Latest Developments in Newcastle Disease Vaccine Market

  • In January 2025, Boehringer Ingelheim Vietnam hosted its inaugural VAXXITEK symposium and unveiled the VAXXITEK HVT + IBD + ND poultry vaccine. This vaccine marks Vietnam's first vector vaccine that targets three diseases with a single dose: Marek's disease, Gumboro disease, and Newcastle disease. The vaccine technology focuses on achieving a balance between effectiveness and safety, which is essential in the development of the final product.
  • In April 2024, Merck Animal Health announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the marketing authorization of the INNOVAX-ND-H5 vaccine under exceptional circumstances, as outlined in Article 25 of Regulation (EU) 2019/6. The vaccine is designed to reduce mortality, clinical symptoms, and virus excretion caused by infection with the highly pathogenic Avian Influenza (HPAI) virus of the H5 type. In addition, INNOVAX-ND-H5 provides active immunity against Marek’s disease and Newcastle disease.
  • In August 2022, the Mount Sinai Health System in New York, NY, introduced CastleVax, Inc., a clinical-stage company focused on vaccine research and development. CastleVax is committed to the commercial advancement of the Newcastle disease virus (NDV) vaccine platform technology, originally developed by Peter Palese and his team. This platform utilizes Newcastle disease virus (NDV), a member of the avian paramyxovirus family (APMV), which is harmless to humans. It has been engineered to enable the creation of both intranasal and intramuscular vaccines targeting emerging SARS-CoV-2 variants, such as the Omicron variants, as well as a broad spectrum of other viral pathogens.
  • In March 2022, a team of clinical researchers at the Icahn School of Medicine at Mount Sinai announced the initiation of a Phase 1, open-label, placebo-controlled study to assess the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19. This vaccine, known as NDV-HXP-S, contains a recombinant Newcastle disease virus that expresses the SARS-CoV-2 spike protein, the virus responsible for COVID-19. It is free from adjuvants and preservatives, and may offer the potential for enhanced immunity against COVID-19.
  • In January 2021, Zoetis announced the expansion of its recombinant vector vaccine portfolio with the introduction of Poulvac Procerta HVT-IBD. This vaccine offers early protection against the current infectious bursal disease (IBD) viruses affecting U.S. broiler flocks. Poulvac Procerta HVT-IBD is an essential tool for managing IBD, providing significant protection and offering early defense against IBD viruses, including the dominant AL2 variant.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Segmentation, By Type of Vaccine (Live Attenuated Vaccines, Inactivated Vaccines, Vector-based Vaccines, DNA Vaccines, and Others), Route of Administration (Subcutaneous, Intramuscular, Oral, Intranasal, and Others), Target Species (Chicken, Duck and Goose, and Other Poultry), Formulation (Lyophilized, Liquid, Suspension, and Emulsion), End-User (Commercial Poultry Farms, Backyard Poultry Farmers, Veterinary Clinics, and Research Institutions)– Industry Trends and Forecast to 2032 .
The Global Newcastle Disease Vaccine Market size was valued at USD 312.45 USD Million in 2024.
The Global Newcastle Disease Vaccine Market is projected to grow at a CAGR of 4.09% during the forecast period of 2025 to 2032.
The market report covers data from U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
Testimonial